In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

A lab scientist peering into a microscope focused on gene editing technology. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a ...

University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

Boston has become one of the top places for biotech research, and one of the big players in this space is CRISPR gene-editing ...

Nobel Prize winner and UC Berkeley professor Jennifer Doudna presented developments on her gene research at a UC Santa Barbara Arts & Lectures event on Oct. 22.

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Techniques such as Polymerase Chain Reaction (PCR), CRISPR-Cas9 gene editing, and recombinant DNA technology have ...

UW–Madison researchers used gene therapy to prevent hereditary spastic paraplegia (HSP) in a rat model, introducing a healthy ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage biotech company focused on developing CRISPR-Cas9 gene-editing therapies for both in vivo and ex vivo applications. The company’s ...